Currently, one topical JAK-STAT inhibitor (ruxolitinib) for mild-to-moderate AD and two oral formulations (abrocitinib and upadacitinib) for moderate-to-severe AD are approved by the FDA. The gene discussed is SOAT1; the disease is Alzheimer disease.